Grants and Contributions

About this information

In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.

The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.

Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.

Found four records

$187,700.00

Nov 1, 2021

For-profit organization

Agreement:

Development of a Deuterated Analogue of a Novel Therapeutic for Blood Cancers

Agreement Number:

980902

Duration: from Nov 1, 2021 to Dec 31, 2022
Description:

This project will enable the creation and optimization of deuterated PCLX-001 analogues designed to improve the therapeutic index of PCLX-001 and bring to market an improved compound: deuterated variants of drugs can resist metabolic degradation in vivo which can increase the half-life in a patient and, consequently, both i) enable a lower dose while maintaining a similar efficacy, and ii) decrease Cmax based side-effects.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Edmonton, Alberta, CA T5J 4P6

$108,000.00

Jan 3, 2017
Organization: National Research Council Canada
Location: Edmonton, Alberta, CA

$158,000.00

Jan 3, 2017
Organization: National Research Council Canada
Location: Edmonton, Alberta, CA

$158,000.00

Jan 1, 2017

For-profit organization

Agreement:

Pre-clinical Development of a Novel Personalized Treatment for B Cell Lymphomas

Agreement Number:

878946

Duration: from Jan 1, 2017 to Dec 31, 2018
Description:

Pacylex has discovered a biomarker that is lower in certain cancers than normal tissue and that confers sensitivity to our drug. With extensive proof-of-efficacies on our precision medicine strategy in vitro and in vivo in hand, this project enables the next steps of animal safety testing of our lead drug PCLX-001 and further mechanism of action studies to enable an investigative new drug (IND) Health Canada filing so we can eventually start Phase I trials, ideally in Edmonton, AB, Canada.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Edmonton, Alberta, CA T5Y 3K7